Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment
Can-Fite BioPharma Ltd (NYSE American: CANF) announced that the Chinese National Intellectual Property Administration granted a Notice of Allowance for its patent on an A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation. This patent supports their liver drug candidate, Namodenoson, which is set to enter Phase IIb trials for non-alcoholic steatohepatitis (NASH) in Q3 2021, following successful Phase IIa results. Namodenoson has been licensed in China with potential milestone payments of up to $74.5 million. The NASH market in China is projected to reach $6.4 billion by 2027.
- Grant of patent by Chinese National Intellectual Property Administration supports Namodenoson's development.
- Successful Phase IIa study results in reducing liver fat and inhibiting fibrosis for Namodenoson.
- Expected milestone payments of up to $74.5 million from licensing deal in China.
- None.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Chinese National Intellectual Property Administration has issued a Notice of Allowance for its patent titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”. This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fite’s drug platform technology, to reduce liver fat particularly in patients with non-alcoholic steatohepatitis (NASH).
Can-Fite expects to commence a Phase IIb study for its liver drug candidate Namodenoson in the treatment of NASH in Q3 2021 based on a successfully concluded Phase IIa study in which Namodenoson was shown to reduce liver fat content and inhibit fibrosis.
Namodenoson has been out licensed for the treatment of NASH in China and is part of a deal worth up to
“As we prepare to commence enrollment next quarter for our Phase IIb study of Namodenoson in the treatment of NASH, we are very pleased to build our patent estate around our technology in this high-value indication. This latest NASH patent adds to those already issued in the U.S., Europe, and South Korea,” stated Can-Fite CEO Dr. Pnina Fishman.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005527/en/
FAQ
What is the latest patent news for Can-Fite BioPharma (CANF)?
When will Can-Fite start its Phase IIb study for Namodenoson?
What are the projected market values for NASH treatments in China?
What is Can-Fite BioPharma's milestone payment potential for its drug candidate in China?
What were the results of the Phase IIa study for Namodenoson?
